Squarepoint
IMDX

Squarepoint’s Insight Molecular Diagnostics IMDX Stock Holding History

Squarepoint’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,077
Closed -$47K – 3320
2021
Q4 		$47K Sell
1,077
-2,894
-73% -$166K ﹤0.01% 3029
2021
Q3 		$283K Buy
3,971
+515
+15% +$47.3K ﹤0.01% 2288
2021
Q2 		$397K Sell
3,456
-658
-16% -$64.2K ﹤0.01% 2311
2021
Q1 		$427K Buy
+4,114
New +$391K ﹤0.01% 2142
2020
Q3 		– Sell
-1,069
Closed -$41K – 2737
2020
Q2 		$41K Buy
1,069
+530
+98% +$27.4K ﹤0.01% 2116
2020
Q1 		$26K Buy
+539
New +$26.4K ﹤0.01% 1765

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Squarepoint's IMDX Position: Q1 2022 in Review

Squarepoint sold out of Insight Molecular Diagnostics (IMDX) in Q1 2022, closing a stake of 1,077 shares — an estimated $47K sold.

Squarepoint first reported a position in IMDX in Q1 2020 and held it in 6 quarters. The position peaked at $427K in Q1 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Squarepoint reported no remaining Insight Molecular Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Squarepoint sold 1,077 Insight Molecular Diagnostics shares in Q1 2022, an estimated $47K.
  • Squarepoint first reported a position in Insight Molecular Diagnostics in Q1 2020 and held it in 6 quarters.
  • Squarepoint's Insight Molecular Diagnostics position peaked at $427K in Q1 2021.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.